Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07822529) titled 'A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory Bowel Disease' on Sept. 11.
Study Type: Observational
Primary Sponsor: Janssen Research & Development, LLC
Condition:
Inflammatory Bowel Diseases
Recruitment Status: Not recruiting
Date of First Enrollment: September 18, 2026
Target Sample Size: 400
To know more, visit https://clinicaltrials.gov/study/NCT07822529
Disclaimer: Curated by HT Syndication....